AstraZeneca agrees strategic transaction with Almirall in respiratory disease
Wednesday, 30 July 2014
AstraZeneca today announced that it has entered an agreement to transfer to the company the rights to Almirall's respiratory franchise for an initial consideration of $875 million on completion, and up to $1.22 billion in development, launch, and sales-related milestones. AstraZeneca has also agreed to make various sales-related payments.
The Bayer Group was again successful in the second quarter of 2014. Sales of the Bayer Group rose by 0.9 percent in the second quarter of 2014 to EUR 10,458 million (Q2 2013: EUR 10,360 million). Adjusted for currency and portfolio effects (Fx & portfolio adj.), sales advanced by 6.3 percent.
Five daily portions of fruit and vegetables may be enough to lower risk of death
Tuesday, 29 July 2014
These results conflict with a recent study published in BMJ's Journal of Epidemiology and Community Health suggesting that seven or more daily portions of fruits and vegetables were linked to lowest risk of death. There is growing evidence that increasing fruit and vegetable consumption is related to a lower risk of death from cardiovascular disease and cancer.
Scientists discover new, noncommittal mechanism of drug resistance
Monday, 28 July 2014
Microorganisms like bacteria and fungi can evade treatment by acquiring mutations in the genes targeted by antibiotics or antifungal drugs. These permanent mutations were once thought to be the only way for drug-resistant strains to evolve. Now a new study has shown that microorganisms can use a temporary silencing of drug targets - known as epimutations - to gain the benefits of drug resistance without the commitment.
Drugs used to treat lung disease work with the body clock
Monday, 28 July 2014
Scientists from The University of Manchester have discovered why medication to treat asthma and pneumonia can become ineffective. The findings, published in Nature Medicine, show that drugs widely used to treat lung diseases work with the body clock. In the UK pneumonia, which is caused by an infection, affects around 1 in 1000 adults each year and is more serious for babies, young children, the elderly, smokers and those with an underlying health condition.
Bristol-Myers Squibb reports second quarter 2014 financial results
Friday, 25 July 2014
Bristol-Myers Squibb Company (NYSE:BMY) has reported financial results for the second quarter of 2014, which was highlighted by strong global sales for the company's key brands; the achievement of important regulatory milestones for key brands in Japan, Europe and the U.S.; a new strategic immuno-oncology collaboration agreement with Ono Pharmaceutical Co., Ltd.; and the initiation of several research collaborations that will strengthen the company's leadership position in immuno-oncology.
Paracetamol no better than placebo for lower back pain
Thursday, 24 July 2014
Paracetamol is no better than placebo at speeding recovery from acute episodes of lower back pain or improving pain levels, function, sleep, or quality of life, according to the first large randomised trial to compare the effectiveness of paracetamol with placebo for low-back pain. The findings, published in The Lancet, question the universal endorsement of paracetamol as the first choice painkiller for low-back pain, say the authors.